PBS Biotech

We deliver the next generation of bioprocess technologies by leveraging the strengths of process intensification and chaining. Utilizing the scale-X™ hydro system, BIONET aims to enhance the production of extracellular vesicles produced by Mesenchymal Stem Cells (MSCs) for clinical use. This development is a notable advancement in the mass production of standardized cell and gene therapies. Obio will leverage the NevoLine™ Upstream biomanufacturing platform with scale-X™ bioreactors of Univercells Technologies in OBiO’s recently expanded GMP facility in Shangai to accelerate gene therapy manufacturing. The critical investment was made to deliver a deeper level of support and supply chain security to biomanufacturers. TFBS will leverage the scale-X™ carbo mid-scale fixed-bed bioreactor from Univercells Technologies for good manufacturing practice (GMP) viral vector operations at the expanding state-of-the-art Taipei facility. CBET becomes first US-based training partner for Univercells Technologies; partnership provides opportunities to prepare ACPHS students for successful careers in cell and gene therapy. Partnership will optimize manufacturing of extracellular vesicles (EVs) using scalable and continuous bioprocessing technologies to propel the commercialization of regenerative therapies at affordable costs.

Bioprocess manufacturing includes serveral key components to improve product yield. As part of the bioprocess equipment manufacturers worlwide, our systems are perfect for research and development up to commercial or manufacturing scale. CelCradle is a bench-scale bioreactor system that can support high adherent cell density culture. It is a single-use, cost effective packed-bed bioreactor system for adherent scale-up from laboratory scale to production scale. The ready-to-use bottles, as part of single-use manufacturing, helps eliminate validation costs as compared to multiple-use system when starting on your next cell culture run. With iTide, our newest and latest bioreactors in the pipeline are perfectly curated to provide real-time user experience. Let your eyes take in a visual representation of both bench-scale and closed, automated manufacturing scale bioreactor system for cell culture with just the tip of your cursor. Esco VacciXcell is a division of Esco LifeSciences group that provides bioprocess solutions.

We Develop Cell-based Products Both Within Our Company and Through Our Partner Company. We are therapeutic area agnostic which allows us maximum flexibility to focus on advancing cutting-edge cell-based immuno-therapeutics approaches in oncology across multiple types of solid cancer. Cell BioEngines, Inc., is a clinical-stage biotech company focused on developing 'off-the-shelf' allogeneic cell therapies as 'drugs' to turn all cancers into curable diseases. Established in December 2022, the company's revolutionary science includes single cell discoveries from Harvard Medical School, and in-licensing manufacturing process technology from Icahn School of Medicine at Mount Sinai. Stem Cells Expansion and Differentiation to Manufacture Potent Cells for Clinical Use. Cellular Immunotherapy Product Candidates to Transform Medicine and Healthcare. Allows us to pursue a broad range of products and product candidates with high clinical and commercial potential. Low cost manufacturing enables us to act quickly to seize time-sensitive opportunities and provides us with a wider range of options from which to select the most ideal financial structure for each product.

Our mission is to accelerate scientific discovery by generating world-class biomaterials and conducting groundbreaking research in biobanking, personalized medicine and stem cell biology. Cedars-Sinai Biomanufacturing Center (CBC) is a 22,000 square foot, state-of-the-art biomanufacturing facility located in West Hollywood, California. The CBC is comprised of a cGMP cell manufacturing facility, housing multiple cleanroom cell production suites, and process development rooms for producing the next generation of cell and gene therapies. With combined expertise and a cGMP-compliant approach to manufacture cells at scale, the CBC will overcome many challenges by building innovative technologies, connecting protocols, up-scaling of processes and achieving Food and Drug Administration standards for all steps involved to bring innovative cell therapy solutions to researchers and translation scientists. With our world-class expertise in stem cell (iPSC) biology, bioprocessing, translational medicine and manufacturing, the CBC is providing a much-needed biomanufacturing center in Southern California. Our GMP manufacturing facility includes seven process suites for producing the next generation of cell and gene therapies. Equipment in the CBC supports academic, clinical and commercial researchers and investigators to provide for the development and scalable manufacture of clinical-grade cell therapy products in compliance with current cGMP regulations suitable for investigational use in humans; development of iPSC-based and gene-edited cell products for research and drug discovery programs; and training of multiple individuals per week in iPSC and cGMP technologies. We expect to spur economic growth in regenerative medicine with innovative manufacturing in this region of clinical-grade regenerative therapies suitable for investigational use in humans.

We develop, optimize, and engineer robust, GMP-compliant cell manufacturing processes that are specifically tailored to our customers’ cell therapy needs. We are known for our unparalleled commitment to innovation and technical excellence, drawing on our own time-tested technologies and resources. We are a division of Miltenyi Biotec, a pioneering innovator and provider of cell processing and analytical platforms, LVVs, and ancillary materials in this field. Our mission is to improve the availability and affordability of advanced CGT products. We provide services, expertise, and technologies to leading researchers, biotech companies, and large corporates to take their cell and gene therapy products to the next level. With our expertise, breakthrough platforms, and tailored service offerings, Miltenyi Bioindustry helps from early clinical trials to large-scale global operations. With this, Miltenyi Bioindustry is able to offer an all-inclusive platform and service package to add true value to your therapy products. Our acquisition and integration of the lentiviral vector manufacturing business from Lentigen, and Living Pharma’s CAR T cell therapy technology, has strengthened this still further, allowing us to offer lentiviral vector and cell manufacturing services on a larger scale.

CellBios is the only Indian company to develop products in medical & Biotechnology sector. We are the first in India and second in Asia to manufacture Freezing bags and Transfer bag sets for cord blood industry and first to manufacture products for Biotechnology / Bio-Process industries. CellBios is always going through a transformation to advance in this competitive world with important investments in product development for the improvement of human health. CellBios, offering new insights and manufacturing solutions to customers to achieve a breakthrough in healthcare. CellBios business is divided into five business units such as Bio-Banking (Freezing Bags, Transfer Freezing Bag, Transfer Bags, Accessories), Bio-Process (UpStream Bioprocessing, DownStream Bioprocessing, Manifold Transfer Sets, Sampling Bags, Storage Bags), Cell Therapy ( Bone Marrow Transplantation, Cord Blood Transplantation, Cord Blood Storage, Cryo Storage / Cryo Preservation, Stem Cell & Regenerative Medicine) & Medical (Urology, Nephro Care, Critical Care, Cardio Care, Infusion & Drug Delivery, Respiro Care, In-vitro Fertilisation) to serve these market segments in a more scientific and focused approach. CellBios R&D team focused on creating innovative solutions for providing better life. We provide service to our customers to expedite results with enhanced efficiency, technology transfers & meeting regulatory requirements. CellBios offers various products to meet customer expectations.